FABOMOTIZOLE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21N3O2S.ClH
Molecular Weight	343.872
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC1=CC2=C(C=C1)N=C(N2)SCCN3CCOCC3

InChI

InChIKey=MYSRFAUFQZYTOV-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S.ClH/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18;/h3-4,11H,2,5-10H2,1H3,(H,16,17);1H

HIDE SMILES / InChI

Description
Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf
Curator's Comment: description was created based on several sources, including http://pro-pharma.biz/?page_id=171

Fabomotizole (also known as Afobazole) is a selective non-benzodiazepine anxiolytic which was developed in Russia and launched in 2006. The drug is used for the treatment of wide range of diseases: generalized anxious disorders, neurasthenia, adaptation disorders, sleep disorders, for alleviation of withdrawal syndrome. According to the drug label (in Russian), its action is related to the interaction with sigma-1 receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Agonist 2678		5.9 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Generalized anxiety disorder 32 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Neurasthenia 5 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Adjustment disorder 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Insomnia 108 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Withdrawal syndrome 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Palliative	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006

PubMed

Title	Date	PubMed
[Afobazole increases cerebral blood flow in rats with global brain ischemia].	2004 Sep-Oct	15559627
[Aphobazol--new selective anxyolytic drug].	2005	15875941
[Using aphobazol for treatment of the emotional stress after exposure to ionizing radiation].	2005 Apr-Jun	16078648
[Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon].	2005 Jan-Feb	15786959
[Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction].	2006 May-Jun	16878488
[Antimutagenic and antiteratogenic properties of afobazole].	2009 Jan-Feb	19334511
[Specific effects of selective anxiolytic afobazole on the cardiovascular system].	2009 Jan-Feb	19334510
[Afobazole effect on heart rate variability in rats with different behaviors in the "open field" test].	2009 Jan-Feb	19334509
[Effects of afobazole on the stress protein HSP70 level in the brain tissue of rats with global transient ischemia].	2009 Jan-Feb	19334508
[Neuroprotective effects of afobazole in a hemorrhagic stroke model].	2009 Jan-Feb	19334507
[Afobazole decreases motor side effects induced by haloperidol].	2009 Jan-Feb	19334504
Interaction of afobazole with sigma1-receptors.	2009 Jul	19902093
Effect of afobazole on mitochondrial monoamine oxidase A activity in vitro.	2009 Jul	19902087
[Afobasol efficacy in a model of vagotonic atrial fibrillation].	2010	20540357
[Afobasol antifibrillation activity in animals with the intact and denervated myocardium].	2010	20540356
[Comparative study of the interoceptive effects of afobazole and diazepam].	2010 Oct	21254504
Comparative analysis of tissue availability for afobazole and compound M-11.	2010 Sep	21246091
On the mechanism of antifibrillatory effect of afobazole.	2010 Sep	21246090

Patents

Sample Use Guides

In Vivo Use Guide

For adult persons and children it is recommended to use internally, after meal. Usually it is recommended to use 1 tablet (10 mg) trice per day. The maximum daily dose is 60 mg. The period of therapy is 2-4 weeks. According to doctor prescription it is possible to prolong the period up to 3 months.

Route of Administration: Oral

In Vitro Use Guide

Experiments on immortalized hippocampal cell culture of mice showed that afobazole increases the NGF level in a final concentration of 10(-8) M and the BDNF level in final concentrations from 10(-8) to 10(-5) M.

Name

Type

Language

FABOMOTIZOLE HYDROCHLORIDE

Common Name

English

AFOBAZOLE MONOHYDROCHLORIDE

Common Name

English

1H-BENZIMIDAZOLE, 5-ETHOXY-2-((2-(4-MORPHOLINYL)ETHYL)THIO)-, MONOHYDROCHLORIDE

Common Name

English

APHOBAZOLE MONOHYDROCHLORIDE

Common Name

English

FABOMOTIZOLE MONOHYDROCHLORIDE

Common Name

English

FABOMOTIZOLE HYDROCHLORIDE [MART.]

Common Name

English

1H-BENZIMIDAZOLE, 6-ETHOXY-2-((2-(4-MORPHOLINYL)ETHYL)THIO)-, HYDROCHLORIDE (1:1)

Systematic Name

English

AFOBAZOL MONOHYDROCHLORIDE

Common Name

English

OBENOXAZINE HYDROCHLORIDE

Common Name

English

SM-346

Code

English

Fabomotizole hydrochloride [WHO-DD]

Common Name

English

FABOMOTIZOLE MONOHYDROCHLORIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28197